Generation Bio is a biotechnology company that develops gene therapies for patients with genetic diseases. The company was founded in 2016 and is headquartered in Cambridge, Massachusetts. Generation Bio's proprietary technology platform, called closed-ended DNA, allows for the development of gene therapies that can be delivered to patients through a single dose. The company's lead product candidate is a treatment for phenylketonuria (PKU), a rare genetic disorder that can cause intellectual disability and other health problems. Generation Bio is backed by several venture capital firms and has partnerships with biopharmaceutical companies including Biogen and Novartis.